Mesenchymal Stem Cells as Therapeutic Agents and Novel Carriers for the Delivery of Candidate Genes in Acute Kidney Injury

Table 1

Registered clinical trials involving the use of MSCs in AKI.

ClinicalTrials.gov Identifier	Study title	Study phase	Actual/estimated enrollment	MSC source	Primary outcome	Location	Status
NCT04194671	Clinical Trial of Mesenchymal Stem Cells in the Treatment of Severe Acute Kidney Injury	Phase 1/2	80 participants	Umbilical cord	Progression of renal function within 28 days after receiving MSC	China	Not yet recruiting
NCT01275612	Mesenchymal Stem Cells in Cisplatin-Induced Acute Renal Failure in Patients with Solid Organ Cancers	Phase 1	0 participants	Bone marrow	The rate of renal function loss up to 15 days postcisplatin infusion	Italy	Withdrawn
NCT03015623	A Study of Cell Therapy for Subjects with Acute Kidney Injury Who are Receiving Continuous Renal Replacement Therapy	Phase 1/2	24 participants	Unclear	Outcomes out to day 28 and serious adverse events through day 180	United States	Recruiting
NCT01602328	A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects (ACT-AKI)	Phase 2	156 participants	Bone marrow	Time to kidney recovery	United States	Terminated
NCT00733876	Allogeneic Multipotent Stromal Cell Treatment for Acute Kidney Injury following Cardiac Surgery	Phase 1	15 participants	Unclear	MSC-specific adverse or serious adverse events	United States	Completed
NCT02563366	Effect of BM-MSCs on Early Graft Function Recovery after DCD Kidney Transplant	Phase 1/2	120 participants	Bone marrow	Estimated glomerular filtration rate at one month posttransplant	China	Unknown
NCT02561767	Effect of BM-MSCs in DCD Kidney Transplantation	Phase 1/2	120 participants	Bone marrow	Estimated glomerular filtration rate at one month posttransplant	China	Unknown